Evolus, Inc. (EOLS)
7.14
-0.55
(-7.15%)
USD |
NASDAQ |
Oct 02, 16:00
7.135
0.00 (0.00%)
After-Hours: 20:00
Evolus Enterprise Value : 590.97M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 590.97M |
| October 01, 2026 | 627.28M |
| September 30, 2026 | 647.74M |
| September 29, 2026 | 647.08M |
| September 28, 2026 | 645.10M |
| September 25, 2026 | 645.76M |
| September 24, 2026 | 638.50M |
| September 23, 2026 | 647.74M |
| September 22, 2026 | 664.25M |
| September 21, 2026 | 647.08M |
| September 18, 2026 | 638.50M |
| September 17, 2026 | 648.40M |
| September 16, 2026 | 647.08M |
| September 15, 2026 | 641.80M |
| September 14, 2026 | 643.12M |
| September 11, 2026 | 637.18M |
| September 10, 2026 | 641.80M |
| September 09, 2026 | 685.37M |
| September 08, 2026 | 705.84M |
| September 04, 2026 | 733.56M |
| September 03, 2026 | 717.06M |
| September 02, 2026 | 717.72M |
| September 01, 2026 | 719.04M |
| August 31, 2026 | 719.70M |
| August 28, 2026 | 705.84M |
| Date | Value |
|---|---|
| August 27, 2026 | 705.84M |
| August 26, 2026 | 699.23M |
| August 25, 2026 | 712.11M |
| August 24, 2026 | 699.23M |
| August 21, 2026 | 673.49M |
| August 20, 2026 | 670.85M |
| August 19, 2026 | 687.35M |
| August 18, 2026 | 659.63M |
| August 17, 2026 | 632.56M |
| August 14, 2026 | 657.98M |
| August 13, 2026 | 649.06M |
| August 12, 2026 | 655.67M |
| August 11, 2026 | 670.19M |
| August 10, 2026 | 619.36M |
| August 07, 2026 | 620.68M |
| August 06, 2026 | 608.80M |
| August 05, 2026 | 527.60M |
| August 04, 2026 | 523.64M |
| August 03, 2026 | 519.02M |
| July 31, 2026 | 505.15M |
| July 30, 2026 | 516.38M |
| July 29, 2026 | 517.70M |
| July 28, 2026 | 530.24M |
| July 27, 2026 | 527.60M |
| July 24, 2026 | 514.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.893B |
| Corcept Therapeutics, Inc. | 12.24B |
| Veru, Inc. | 19.69M |
| Johnson & Johnson | 644.86B |
| Eli Lilly & Co. | 1.122T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.052M |
| Revenue (Quarterly) | 84.08M |
| Total Expenses (Quarterly) | 92.14M |
| EPS Diluted (Quarterly) | -0.1221 |
| Gross Profit Margin (Quarterly) | 66.18% |
| Profit Margin (Quarterly) | -9.58% |
| Earnings Yield | -7.38% |
| Normalized Earnings Yield | -7.672 |